Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARD-301
- Development stage
- Unknown
- Lead developer
- Scilex Holding
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**ARD-301** is a proprietary delayed burst release low-dose oral formulation of the opioid receptor antagonist naltrexone being developed as a non-opioid, non-addictive therapy for chronic pain conditions including fibromyalgia and chronic post-COVID (long COVID) syndrome, as well as broader chronic pain indications. It is based on low-dose naltrexone, which at sub-analgesic doses is thought to modulate microglial activation and central pain processing rather than provide classic opioid antagonism, potentially improving a broad range of fibromyalgia symptoms and pain-related outcomes while avoiding dependence or abuse. The drug was originated by Aardvark Therapeutics, which licensed it under an exclusive term sheet to Sorrento Therapeutics and its majority-owned subsidiary Scilex Holding for planned Phase 2 clinical programs in fibromyalgia, chronic pain, and chronic post-COVID syndrome.[7][10][19]
- Other names
- Delayed Burst Release Low Dose Naltrexone
02
Targets
DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on ARD-301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARD-301.